MedTrace Logo

Diagnosis Value of SEMA4C in Breast Cancer

NCT03662633 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2300

Last updated 2022-10-20

No results posted yet for this study

Summary

Breast cancer remains the most common cancer in women worldwide. Early diagnosis can greatly improve the prognosis. To date, imaging examination is still the most important diagnostic and grading tool for breast cancer. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The study is undertaken to evaluate the diagnostic efficiency of SEMA4C.

Conditions

  • Breast Neoplasm Female

Interventions

DIAGNOSTIC_TEST

Breast cancer group

All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.

DIAGNOSTIC_TEST

Benign breast tumor group

All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.

Sponsors & Collaborators

  • Hubei Cancer Hospital

    collaborator OTHER

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Wuhan Central Hospital

    collaborator OTHER

  • Xiangyang Central Hospital

    collaborator OTHER

  • The First People's Hospital of Jingzhou

    collaborator OTHER

  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Qinglei Gao, MD, PhD · Tongji Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2023-09-01
Completion
2024-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03662633 on ClinicalTrials.gov